10-Q: Earth Science Tech Reports Strong Revenue Growth in Q3 2023 Driven by Acquisitions

Earth Science Tech, Inc. reports a significant increase in revenue and profitability for the quarter ended December 31, 2023, primarily due to the acquisition of RxCompound and Peaks.

Summary

• Earth Science Tech, Inc. (ETST) reported its financial results for the quarter ended December 31, 2023.
• The company's revenue increased dramatically to $3,790,112, compared to $2,533 in the same quarter of the previous year.
• This substantial growth is primarily attributed to the acquisitions of RxCompound and Peaks.
• Gross profit for the quarter was $2,376,698, with a gross margin of 62.7%.
• Net profit for the quarter was $225,443, a significant improvement from the $98,464 profit in the same quarter of the previous year.
• The company's total assets increased to $3,245,655, while total liabilities were $1,086,272.
• The company's cash position improved to $205,718 from $35,756 at the beginning of the period.
• The company has reduced its debt obligations through settlements and negotiations.
• The company's plan is to continue to expand its business and intellectual property.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved profitability, but there are still concerns about the company's going concern status, internal controls, and debt levels. The sentiment is positive but tempered by these risks.

Positives

• The company experienced a substantial increase in revenue due to the acquisitions of RxCompound and Peaks.
• The company achieved a significant increase in net profit compared to the same quarter last year.
• The company's cash position has improved significantly.
• The company has successfully reduced its debt obligations.
• The company's total assets have increased significantly.
• The company's gross margin is a healthy 62.7%.

Negatives

• The company has a history of accumulated losses, with an accumulated deficit of $29,922,668.
• The company's internal controls were deemed not effective as of December 31, 2023.
• The company has negative working capital.
• The company has a history of debt and has had to issue shares to settle debts.

Risks

• The company's auditors have expressed doubt about its ability to continue as a going concern.
• The company has a history of accumulated losses and negative working capital.
• The company's internal controls were deemed not effective as of December 31, 2023.
• The company may need to raise additional capital for expansion or acquisitions.
• The company's success is dependent on the continued growth of RxCompound and Peaks.

Future Outlook

The company plans to continue expanding its business, including obtaining more accounts for RxCompound, expanding the states in which it is licensed to fill prescriptions, and developing new intellectual property. The company believes it can operate without needing to raise capital unless needed for acquisitions or expansion.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan and generate sufficient revenues may provide the opportunity for the Company to continue as a going concern.
• Management intends to raise additional funds by way of a public or private offering if needed.
• The company recorded its highest revenue and profit generated month in December 2023.

Industry Context

The company's focus on compounding pharmaceuticals and telemedicine aligns with the growing trends in personalized medicine and remote healthcare services. The company's expansion into sterile compounding positions it to capitalize on the demand for injectable medications. The company's focus on men's health is a niche market with significant growth potential.

Comparison to Industry Standards

• The company's gross margin of 62.7% is within the range of other pharmaceutical and healthcare companies, but it is important to compare this to companies with similar business models.
• The company's revenue growth is significantly higher than many established companies, but this is due to the recent acquisitions and the low base of the previous year.
• The company's profitability is improving, but it is still not consistently profitable, which is common for early-stage companies in the healthcare sector.
• The company's debt levels are still high, but the company has made progress in reducing its debt obligations.
• The company's internal control weaknesses are a concern and need to be addressed to ensure the reliability of financial reporting.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal claims currently pending or, to the company's knowledge, threatened against it or any of its officers or directors that would be likely to have a material adverse effect on its financial position, results of operations, or cash flows.

Related Party Transactions

• Transactions with related parties have been disclosed in debt, acquisition, and officers compensation notes.
• As of December 31, 2023, the Company had no related party balances.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and profitability.
• Employees may benefit from the company's growth and expansion.
• Customers will benefit from the company's expanded product offerings and services.
• Creditors may benefit from the company's improved financial position and ability to repay debts.

Next Steps

• The company plans to continue expanding its business, including obtaining more accounts for RxCompound.
• The company plans to expand the states in which it is licensed to fill prescriptions.
• The company plans to develop new intellectual property.
• The company will continue to evaluate and improve its internal controls over financial reporting.

Key Dates

Keywords

pharmaceuticals, telemedicine, compounding, revenue growth, acquisitions, RxCompound, Peaks, financial results, profitability, health and wellness